March 2015 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013, and the 2014/15 Invitation to Tender, dated 06 November 2014.
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website.
Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
| Chemical name | Presentation;Pack size and type | Current subsidy (and price) | New subsidy (and price) | Hospital SupplyBrand (Supplier) | DVLimit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Ropivacaine hydrochloride |
Inj 2 mg per ml, 200 ml bag; 5 bags |
$265.00 |
$79.50 |
Naropin (AstraZeneca) |
1% |
1 May 2015 |
1 July 2015 |
|
Ropivacaine hydrochloride |
Inj 2 mg per ml, 100 ml bag; 5 bags |
$200.00 |
$60.00 |
Naropin (AstraZeneca) |
1% |
1 May 2015 |
1 July 2015 |
Tenders awarded to listed pharmaceuticals where at least one other brand or pack size is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Current pack price | New packprice | Hospital SupplyBrand (Supplier) | DVLimit | Date of listing/price change for tender winning brand | Hospital Supply Status date (and delisting of other listed brands) | Brand (Supplier) to be delisted |
|---|---|---|---|---|---|---|---|---|
| Ropivacaine hydrochloride | Inj 2 mg per ml, 20 ml ampoule;5 ampoules | $75.00 | $9.50 | Ropivacaine Kabi (Fresenius Kabi) | 1% | 1 June 2015 | 1 August 2015 | Naropin (AstraZeneca) |
| Ropivacaine hydrochloride | Inj 7.5 mg per ml, 10 ml ampoule;5 ampoules | $45.00 | $10.20 | Ropivacaine Kabi (Fresenius Kabi) | 1% | 1 June 2015 | 1 August 2015 | Naropin (AstraZeneca) |
| Ropivacaine hydrochloride | Inj 7.5 mg per ml, 20 ml ampoule;5 ampoules | $84.00 | $12.50 | Ropivacaine Kabi (Fresenius Kabi) | 1% | 1 June 2015 | 1 August 2015 | Naropin (AstraZeneca) |
| Ropivacaine hydrochloride | Inj 10 mg per ml, 10 ml ampoule;5 ampoules | $54.00 | $10.90 | Ropivacaine Kabi (Fresenius Kabi) | 1% | 1 June 2015 | 1 August 2015 | Naropin (AstraZeneca) |
Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
| Chemical name | Presentation; Pack size and type |
Pack Price | Hospital SupplyBrand (Supplier) | DVLimit | Listing date | Hospital Supply Status date |
|---|---|---|---|---|---|---|
| Ropivacaine hydrochloride | Inj 2 mg per ml, 10 ml ampoule;5 ampoules | $9.05 | Ropivacaine Kabi (Fresenius Kabi) | 1% | 1 June 2015 | 1 August 2015 |
| Ropivacaine hydrochloride | Inj 10 mg per ml, 20 ml ampoule;5 ampoules | $16.30 | Ropivacaine Kabi (Fresenius Kabi) | 1% | 1 June 2015 | 1 August 2015 |
2014/15 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2018
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
Tenders awarded to pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current subsidy (and price) |
New subsidy (and price) |
Sole supply brand (Supplier) |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Betamethasone dipropionate with calcipotriol |
Oint 500 mcg with calcipotriol 50 mcg per g; 30 g tube OP |
$26.12 |
$26.12 |
Daivobet (BioCSL) |
1 July 2015 |
1 October 2015 |
|
Betamethasone dipropionate with calcipotriol |
Gel 500 mcg with calcipotriol 50 mcg per g; 30 g tube OP |
$26.12 |
$26.12 |
Daivobet (BioCSL) |
1 July 2015 |
1 October 2015 |
|
Candesartan cilexetil |
Tab 4 mg; 90 tablet bottle pack |
$4.13 |
$2.50 |
Candestar (Mylan) |
1 July 2015 |
1 October 2015 |
|
Candesartan cilexetil |
Tab 8 mg; 90 tablet bottle pack |
$6.10 |
$3.68 |
Candestar (Mylan) |
1 July 2015 |
1 October 2015 |
|
Candesartan cilexetil |
Tab 16 mg; 90 tablet bottle pack |
$10.18 |
$6.12 |
Candestar (Mylan) |
1 July 2015 |
1 October 2015 |
|
Candesartan cilexetil |
Tab 32 mg; 90 tablet bottle pack |
$17.66 |
$10.66 |
Candestar (Mylan) |
1 July 2015 |
1 October 2015 |
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current subsidy (and price) |
New subsidy (and price) |
Sole supply brand (Supplier) |
Date of listing/subsidy change for tender winning brand |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date (and delisting of other listed brands) |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Acarbose |
Tab 50 mg; 90 tablet, blister pack |
$9.82 |
$4.28 |
Glucobay (Bayer) |
1 August 2015 |
1 October 2015 |
1 January 2016 |
Accarb (Mylan) |
|
Acarbose |
Tab 100 mg; 90 tablet, blister pack |
$15.83 |
$7.78 |
Glucobay (Bayer) |
1 August 2015 |
1 October 2015 |
1 January 2016 |
Accarb (Mylan) |
|
Diclofenac sodium |
Tab long-acting 75 mg; 500 tablet, bottle pack |
$24.52 |
$15.20 |
Apo-Diclo SR (Apotex) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Diclax SR (Douglas) |
|
Diclofenac sodium |
Tab long-acting 100 mg; 500 tablet, bottle pack |
$42.25 |
$26.20 |
Apo-Diclo SR (Apotex) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Diclax SR (Douglas) |
|
Diclofenac sodium |
Tab EC 25 mg; 50 tablet, blister pack |
$4.00 per 100 tablets |
$1.30 per 50 tablets |
Diclofenac Sandoz (Sandoz) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Apo-Diclo (Apotex) |
|
Diclofenac sodium |
Tab EC 50 mg; 50 tablet, blister pack |
$16.00 per 500 tablets |
$1.00 per 50 tablets |
Diclofenac Sandoz (Sandoz) |
1 October 2015 |
1 December 2015 |
1 March 2016 |
Apo-Diclo (Apotex) |
|
Hydroxocobalamin |
Inj 1 mg per ml, 1 ml ampoule; 3 ampoules |
$5.10 |
$2.31 |
Neo-B12 (Hospira) |
1 July 2015 |
1 September 2015 |
1 December 2015 |
ABM Hydroxocobalamin (ABM) |
|
Sildenafil |
Tab 25 mg; 4 tablet, blister pack |
$1.85 |
$0.75 |
Vedafil (Mylan) |
1 July 2015 |
1 September 2015 |
1 December 2015 |
Silagra (Actavis) |
|
Sildenafil |
Tab 50 mg; 4 tablet, blister pack |
$1.85 |
$0.75 |
Vedafil (Mylan) |
1 July 2015 |
1 September 2015 |
1 December 2015 |
Silagra (Actavis) |
|
Sildenafil |
Tab 100 mg; 4 tablet, blister pack |
$7.45 |
$2.75 |
Vedafil (Mylan) |
1 July 2015 |
1 September 2015 |
1 December 2015 |
Silagra (Actavis) |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current subsidy (and price) |
New subsidy (and price) |
Hospital Supply Brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Betamethasone dipropionate with calcipotriol |
Oint 500 mcg with calcipotriol 50 mcg per g; 30 g tube OP |
$26.12 |
$26.12 |
Daivobet (BioCSL) |
1% |
1 July 2015 |
1 September 2015 |
|
Betamethasone dipropionate with calcipotriol |
Gel 500 mcg with calcipotriol 50 mcg per g; 30 g tube OP |
$26.12 |
$26.12 |
Daivobet (BioCSL) |
1% |
1 July 2015 |
1 September 2015 |
|
Candesartan cilexetil |
Tab 4 mg; 90 tablet bottle pack |
$4.13 |
$2.50 |
Candestar (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
|
Candesartan cilexetil |
Tab 8 mg; 90 tablet bottle pack |
$6.10 |
$3.68 |
Candestar (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
|
Candesartan cilexetil |
Tab 16 mg; 90 tablet bottle pack |
$10.18 |
$6.12 |
Candestar (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
|
Candesartan cilexetil |
Tab 32 mg; 90 tablet bottle pack |
$17.66 |
$10.66 |
Candestar (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical Name |
Presentation; |
Current subsidy (and price) |
New subsidy (and price) |
Hospital Supply Brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Acarbose |
Tab 50 mg; 90 tablet, blister pack |
$9.82 |
$4.28 |
Glucobay (Bayer) |
1% |
1 August 2015 |
1 October 2015 |
Accarb (Mylan) |
|
Acarbose |
Tab 100 mg; 90 tablet, blister pack |
$15.83 |
$7.78 |
Glucobay (Bayer) |
1% |
1 August 2015 |
1 October 2015 |
Accarb (Mylan) |
|
Diclofenac sodium |
Tab long-acting 75 mg; 500 tablet, bottle pack |
$24.52 |
$15.20 |
Apo-Diclo SR (Apotex) |
1% |
1 October 2015 |
1 December 2015 |
Diclax SR (Douglas) |
|
Diclofenac sodium |
Tab long-acting 100 mg; 500 tablet, bottle pack |
$42.25 |
$26.20 |
Apo-Diclo SR (Apotex) |
1% |
1 October 2015 |
1 December 2015 |
Diclax SR (Douglas) |
|
Diclofenac sodium |
Tab EC 25 mg; 50 tablet, blister pack |
$4.00 per 100 tablets |
$1.30 per 50 tablets |
Diclofenac Sandoz (Sandoz) |
1% |
1 October 2015 |
1 December 2015 |
Apo-Diclo (Apotex) |
|
Diclofenac sodium |
Tab EC 50 mg; 50 tablet, blister pack |
$16.00 per 500 tablets |
$1.00 per 50 tablets |
Diclofenac Sandoz (Sandoz) |
1% |
1 October 2015 |
1 December 2015 |
Apo-Diclo (Apotex) |
|
Hydroxocobalamin |
Inj 1 mg per ml, 1 ml ampoule; 3 ampoules |
$5.10 |
$2.31 |
Neo-B12 (Hospira) |
1% |
1 July 2015 |
1 September 2015 |
ABM Hydroxocobalamin (ABM) |
|
Sildenafil |
Tab 25 mg; 4 tablet, blister pack |
$1.85 |
$0.75 |
Vedafil (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
Silagra (Actavis) |
|
Sildenafil |
Tab 50 mg; 4 tablet, blister pack |
$1.85 |
$0.75 |
Vedafil (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
Silagra (Actavis) |
|
Sildenafil |
Tab 100 mg; 4 tablet, blister pack |
$7.45 |
$2.75 |
Vedafil (Mylan) |
1% |
1 July 2015 |
1 September 2015 |
Silagra (Actavis) |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2014/15 Invitation to Tender, dated 6 November 2014:
2013/14 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Sodium hyaluronate | Inj 23 mg per ml, 0.6 ml syringe |
| Sodium hyaluronate with chondroitin sulphate | Inj 30 mg with chondroitin sulphate 40 mg per ml, 0.75 ml syringe |
2014/15 Invitation to Tender
| Chemical name | Line item |
|---|---|
| Adapalene | Crm 0.1% |
| Adapalene | Gel 0.1% |
| Beclomethasone Dipropionate | Metered aqueous nasal spray, 50 mcg per dose |
| Beclomethasone Dipropionate | Metered aqueous nasal spray, 100 mcg per dose |
| Budesonide | Metered aqueous nasal spray, 50 mcg per dose |
| Budesonide | Metered aqueous nasal spray, 100 mcg per dose |
| Dorzolamide hydrochloride | Eye drops 2% |
| Risperidone | Orally-disintegrating tablets 0.5 mg |
| Risperidone | Orally-disintegrating tablets 1 mg |
| Risperidone | Orally-disintegrating tablets 2 mg |
For products included in the 2013/14 and 2014/15 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.